THERAPEUTIC MANAGEMENT OF DYSLEXIA
DOI:
https://doi.org/10.56238/isevmjv5n2-016Keywords:
Dyslexia, Learning Disorders, Diagnosis, Treatment, NeuroscienceAbstract
Dyslexia is a specific learning disorder of neurobiological origin that primarily affects reading fluency, word decoding, and spelling skills, and is associated with functional and structural alterations in neural networks responsible for phonological processing. The present study aimed to analyze recent scientific evidence regarding the therapeutic management of dyslexia. This is a narrative bibliographic review conducted using the PubMed database, employing the descriptors dyslexia, treatment, and diagnosis, combined with Boolean operators. Articles published in the last five years, available in full text in Portuguese or English, and directly related to the topic were included. The results indicate that dyslexia has a heterogeneous etiology, involving deficits in phonological, visual, and auditory processing, making accurate differential diagnosis essential to guide effective therapeutic interventions. Educational programs based on phonological training remain the most widely used approach, although they show moderate effects. In this context, personalized therapeutic strategies, based on the identification of specific cognitive mechanisms, demonstrate greater potential effectiveness. Emerging technologies, such as non-invasive brain stimulation and artificial intelligence-based tools, have expanded diagnostic and therapeutic possibilities. It is concluded that dyslexia management should involve a multidimensional approach, integrating educational interventions, technological advances, and psychosocial support, with the aim of improving academic performance and promoting cognitive health throughout life.
References
Ali Sulafa, K. M., et al. (2024). Sudan's rheumatic fever and rheumatic heart disease guidelines: A simplified approach in an endemic country. Frontiers in Cardiovascular Medicine, 11, 1403131.
Auala, T., et al. (2022). Acute rheumatic fever and rheumatic heart disease: Highlighting the role of Group A Streptococcus in the global burden of cardiovascular disease. Pathogens, 11(5), 496.
Bray, J. J. H., et al. (2024). Long-term antibiotic prophylaxis for prevention of rheumatic fever recurrence and progression to rheumatic heart disease. Cochrane Database of Systematic Reviews, (9), CD015779.
Dougherty, S., et al. (2023). Rheumatic heart disease. Journal of the American College of Cardiology, 81(1), 81–98.
Ralph, A. P., & Currie, B. J. (2022). Therapeutics for rheumatic fever and rheumatic heart disease. Australian Prescriber, 45(4), 104–112.
Tu'akoi, S., et al. (2023). Addressing rheumatic fever inequities in Aotearoa New Zealand: A scoping review of prevention interventions. Journal of Primary Health Care, 15(1), 59–69.
Downloads
Published
Issue
Section
License

This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.